REGENXBIO, Inc.
(NASDAQ : RGNX)

( )
RGNX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.80%69.520.0%$2233.03m
NVAXNovavax, Inc. -16.77%124.4299.2%$975.55m
SRNESorrento Therapeutics, Inc. -11.92%12.411.5%$660.63m
GILDGilead Sciences, Inc. 1.09%68.841.0%$572.71m
AMGNAmgen, Inc. 3.01%241.721.3%$487.38m
REGNRegeneron Pharmaceuticals, Inc. 2.25%612.352.7%$403.88m
VRTXVertex Pharmaceuticals, Inc. 3.43%270.851.9%$372.31m
BNTXBioNTech SE 0.96%69.110.0%$367.35m
BIIBBiogen, Inc. 1.13%293.221.6%$358.10m
ILMNIllumina, Inc. 0.86%344.143.5%$335.56m
VXRTVaxart, Inc. -14.42%9.200.0%$307.65m
ATNMActinium Pharmaceuticals, Inc. -0.31%9.6313.3%$235.99m
EBSEmergent BioSolutions, Inc. 6.00%129.676.4%$186.47m
ALXNAlexion Pharmaceuticals, Inc. 1.52%102.782.0%$167.42m
SGENSeattle Genetics, Inc. 3.46%158.796.2%$160.84m

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.